Acer Therapeutics to Participate in H.C. Wainwright Global Investment Conference
Acer Therapeutics Inc. (Nasdaq: ACER) announced its participation in the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Acer Therapeutics Inc. (Nasdaq: ACER) announced its participation in the H.C. Wainwright Global Investment Conference from May 24-26, 2022. The event will feature an on-demand recorded presentation and one-on-one virtual meetings starting at 7:00 am ET on May 24. Acer focuses on therapies for serious, rare diseases with unmet medical needs, including programs like ACER-001 for metabolic disorders and ACER-801 for induced vasomotor symptoms. The company aims to develop treatments with favorable safety profiles and accelerated regulatory paths.
Details
News Market Reaction – ACER
The recorded move for ACER in the trading session of this news was -2.68%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEWTON, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that Acer’s management team will virtually present at, and participate in, the H.C. Wainwright Global Investment Conference May 24-26, 2022.
| Format: | On-demand recorded virtual presentation and one-on-one virtual meetings |
| Date: | On-demand presentation available beginning at 7:00 am ET, May 24, 2022 |
| Webcast: | https://journey.ct.events/view/2b639762-a11f-4570-8694-012c299884ce |
About Acer Therapeutics Inc.
Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. Acer’s pipeline includes four programs: ACER-001 (sodium phenylbutyrate) for treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); ACER-801 (osanetant) for treatment of induced Vasomotor Symptoms (iVMS); EDSIVO™ (celiprolol) for treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; and ACER-2820 (emetine), a host-directed therapy against a variety of viruses, including cytomegalovirus, zika, dengue, ebola and COVID-19. Each of Acer’s product candidates is believed to present a comparatively de-risked profile, having one or more of a favorable safety profile, clinical proof-of-concept data, mechanistic differentiation and/or accelerated paths for development through specific programs and procedures established by the FDA. For more information, visit www.acertx.com.
Corporate and IR Contact:
Jim DeNike
Acer Therapeutics Inc.
Ph: 844-902-6100
jdenike@acertx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.